MDGL reports Q2 sales of $364 million
MDGL said Q2 sales reached $364 million. The company also reported over 50,000 patients treated and described market uptake alongside a pipeline advancing.
Q2 sales reached $364 million, and more than 50,000 patients were treated. The product has a first-mover position in an underpenetrated market, with broad payer access in place and a pipeline moving ahead. The company cited double-digit growth and expanding presc...